HALEOSLABS · Healthcare · Biotechnology
Composite scorecard: 39/100 — Quality 36 · Valuation 11 · Momentum 92
| Share price | ₹1,589.10 |
| Market cap | ₹483 Cr |
| P/E ratio | 27.0 |
| P/B ratio | 2.3 |
| ROCE | 10.6% |
| Dividend yield | 0.09% |
| Book value | ₹705.78 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹334 Cr | ₹18 Cr | 13.0% |
| 2025 | ₹345 Cr | ₹19 Cr | 13.0% |
| 2024 | ₹306 Cr | ₹6 Cr | 10.0% |
| 2023 | ₹316 Cr | ₹11 Cr | 9.0% |
| 2022 | ₹350 Cr | ₹25 Cr | 10.0% |
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos